Long Term Open Label Continuation Study

Completed · Phase 3

Conditions studied: Rheumatoid Arthritis

In brief

The purpose of the study was to assess the long-term safety and clinical efficacy following repeated administration of adalimumab in patients with rheumatoid arthritis.

Key facts

Study ID

NCT00195650

Run by

Abbott

People needed

846

Starts

2000-07-01

Expected to finish

2011-05-01

Last updated by the study team

2012-08-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant was in a prior D2E7 (adalimumab) study
• Participant was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.

You may not qualify if…

• Participant was considered by the investigator, for any reason, to be an unsuitable candidate for the study
• Participant was a female subject who is pregnant or breast-feeding or considering becoming pregnant
• Participant had any ongoing chronic or active infection

Where it is running

• Site Reference ID/Investigator# 4111 — Birmingham, Alabama, United States
• Site Reference ID/Investigator# 4113 — Mobile, Alabama, United States
• Site Reference ID/Investigator# 408 — Anchorage, Alaska, United States
• Site Reference ID/Investigator# 537 — Tucson, Arizona, United States
• Site Reference ID/Investigator# 66822 — Anaheim, California, United States
• Site Reference ID/Investigator# 557 — La Jolla, California, United States
• Site Reference ID/Investigator# 387 — Los Angeles, California, United States
• Site Reference ID/Investigator# 555 — Los Angeles, California, United States
• Site Reference ID/Investigator# 552 — Santa Barbara, California, United States
• Site Reference ID/Investigator# 66864 — Santa Monica, California, United States
• Site Reference ID/Investigator# 535 — Stanford, California, United States
• Site Reference ID/Investigator# 3412 — Upland, California, United States
• Site Reference ID/Investigator# 451 — Westlake Village, California, United States
• Site Reference ID/Investigator# 572 — Colorado Springs, Colorado, United States
• Site Reference ID/Investigator# 4109 — Denver, Colorado, United States
• Site Reference ID/Investigator# 541 — Danbury, Connecticut, United States
• Site Reference ID/Investigator# 654 — Milford, Connecticut, United States
• Site Reference ID/Investigator# 655 — Wilmington, Delaware, United States
• Site Reference ID/Investigator# 455 — Daytona Beach, Florida, United States
• Site Reference ID/Investigator# 431 — Fort Lauderdale, Florida, United States
• Site Reference ID/Investigator# 574 — Fort Myers, Florida, United States
• Site Reference ID/Investigator# 66843 — Gainesville, Florida, United States
• Site Reference ID/Investigator# 579 — Orlando, Florida, United States
• Site Reference ID/Investigator# 571 — Palm Harbor, Florida, United States
• Site Reference ID/Investigator# 538 — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.